Semaglutide, a glucagon like peptide-one (GLP-1) receptor agonist, is accessible as monotherapy in both equally subcutaneous as well as oral dosage kind (very first accredited oral GLP-one receptor agonist). It has been authorized for a 2nd line remedy option for superior glycaemic Regulate in form 2 diabetic issues and at https://motherr998dpa1.blogoxo.com/profile